Abstract
Objective: The present study aimed to compare the efficacy and safety of haloperidol with placebo in firstepisode schizophrenia.Place and Time: The sample (n=64) was selected from the outpatient department of the Sir Cows Jee JehangirInstitute of Psychiatry Hyderabad (CJIP). The selected patients were admitted and randomly grouped (32) to receive haloperidol and placebo (multivitamin). This study was single blinded. Duration of study was three monthsfrom Jan 2011 to March 2011.Results: Improvements in PANSS, PBRS score from baseline, by haloperidol week-1 2.6 ± 1.63, .67, by placebo1 results showed < 0.05 siginificant. In week-2 3.14 ± 1.95, .74, by placebo 1.50 ± .71, 50, results showed <0.05significant. In week-3 2.6 ± 1.63, .67 results showed <0.05 significant. In week-4 3.00 ± 1.58, .71. by placebo 1results showed <0.05 significant. In week-5 2.50 ± 1.29, .65, by placebo 1 results showed >0.05 insignificant. Inweek-6 3.00 ± 1.58,.71, by placebo1 results showed >0.05 insignificant.Conclusion: In patients with schizophrenia, haloperidol is better than placebo for disease improvement but increases the rates of parkinsonism, akathisia, and acute dystonias substantially.Key Words: Psychosis, Schizophrenia, Haloperidol, Placebo, Akathesia, Dystonia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
